Covid 19 Research using Clinical Trials (Home Page)
Standard Medical TreatmentWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (6)
Correlated MeSH Terms (1)
|
Name (Synonyms) |
Correlation |
D018352 | Coronavirus Infections NIH | 0.07 |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There are 3 clinical trials
Clinical Trials
The purpose of the study is to determine if high dose Intravenous IVIG plus SMT can reduce
the proportion of participants dying or requiring intensive care unit (ICU) admission on or
before Day 29 or who are dependent on high flow oxygen devices or invasive mechanical
ventilation on Day 29 versus SMT alone in hospitalized participants with COVID-19.
NCT04432324 COVID-19 Biological: Intravenous Immune Globulin Drug: Standard Medical Treatment
Primary Outcomes
Measure: Percentage of Participants Dying or Requiring ICU Admission Time: Up to Day 29
Measure: Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation Time: Day 29
Secondary Outcomes
Measure: Change from Baseline in National Early Warning Score (NEWS) Time: Day 1 through Day 29
Measure: Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours Time: Day 1 through Day 29
Measure: Time to Hospital Discharge Time: Day 1 through Day 29
Measure: Duration of ICU Stay Time: Up to Day 29
Measure: Duration of Any Oxygen Use Time: Day 1 through Day 29
Measure: Duration of Mechanical Ventilation Time: Up to Day 29
Measure: Absolute Value and Mean Change from Baseline in Ordinal Scale Time: Day 1 through Day 29
Measure: Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale Time: Day 15 and Day 29
Measure: Time to Sustained Normalization of Temperature Time: Day 1 through Day 29
Measure: Percentage of Participants with Normalization of Fever Time: Day 1 through Day 29
Measure: Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS) Time: Day 29
Measure: Length of Time to Clinical Progression Time: Up to Day 29
The purpose of the study is to determine if a high dose of IVIG plus SMT can reduce all-cause
mortality versus SMT alone in hospitalized participants with COVID-19 requiring admission to
the ICU through Day 29.
NCT04480424 COVID-19 Biological: GAMUNEX-C Drug: Standard Medical Treatment
Primary Outcomes
Measure: All-Cause Mortality Rate Through Day 29 Time: Up to Day 29
Secondary Outcomes
Measure: Time to Actual ICU Discharge Time: Day 1 through Day 29
Measure: Duration of Mechanical Ventilation Time: Day 1 through Day 29
Measure: Time to Actual Hospital Discharge Time: Day 1 through Day 29
Measure: Duration of Any Oxygen Use Time: Day 1 through Day 29
Measure: Absolute Value and Mean Change from Baseline in Ordinal Scale Time: Day 1 through Day 29
Measure: Percentage of Participants in Each Severity Category of the 7-Point Ordinal Scale Time: Day 15, Day 29
Measure: Overall Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS) Time: Up to Day 29
Measure: Number of Participants who Develop ARDS Distributed by Severity Time: Up to Day 29
Measure: Change from Baseline in Sequential Organ Failure Assessment (SOFA) Score Time: Days 5, 15, and 29
Measure: Change from Baseline in National Early Warning Score (NEWS) Time: Day 1 through Day 29
Measure: Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours Time: Day 1 through Day 29
The primary objective of the study is to determine if Prolastin plus SMT can reduce the
proportion of participants dying or requiring intensive care unit (ICU) admission on or
before Day 15 or who are dependent on invasive mechanical ventilation on Day 15 versus SMT
alone in hospitalized participants with Coronavirus disease 2019 (COVID-19).
NCT04495101 COVID-19 Biological: Prolastin Drug: Standard Medical Treatment
Primary Outcomes
Measure: Percentage of Participants Dying or Requiring ICU Admission Time: Up to Day 15
Measure: Percentage of Participants Who are Dependent on Invasive Mechanical Ventilation Time: Day 15
Secondary Outcomes
Measure: Change from Baseline in National Early Warning Score (NEWS) Time: Day 1 through Day 29
Measure: Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours Time: Day 1 through Day 29
Measure: Time to Hospital Discharge Time: Day 1 through Day 29
Measure: Duration of ICU Stay Time: Up to Day 29
Measure: Duration of Any Oxygen Use Time: Day 1 through Day 29
Measure: Duration of Mechanical Ventilation Time: Up to Day 29
Measure: Mean Change from Baseline in Ordinal Scale Time: Day 1 through Day 29
Measure: Absolute Value Change from Baseline in Ordinal Scale Time: Day 1 through Day 29
Measure: Percentage of Participants in Each Severity Category of the 7-Point Ordinal Scale Time: Day 15, Day 29
Measure: Time to Sustained Normalization of Temperature Time: Day 1 through Day 29
Measure: Percentage of Participants who Sustained Normalization of Temperature Time: Day 1 through Day 29
Measure: Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS) Time: Up to Day 29
Measure: Length of Time to Clinical Progression Time: Up to Day 29
Measure: Mortality Through Day 29 Time: Up to Day 29
No related HPO nodes (Using clinical trials)